Aadi Bioscience Inc
Change company Symbol lookup
Select an option...
AADI Aadi Bioscience Inc
AAPL Apple Inc
ESI Element Solutions Inc
STXB Spirit of Texas Bancshares Inc
ED Consolidated Edison Inc
SNAP Snap Inc
THQ Tekla Healthcare Opportunities Fund
TGIOY Tung Ho Steel Enterprise Corp
RETA Reata Pharmaceuticals Inc
VEL Velocity Financial Inc

Company profile

Aadi Bioscience, Inc, formerly Aerpio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing precision therapies for genetically defined cancers. It develops therapies for cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. Its lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models2. Its nab platform allows for intratumoral drug accumulation and mTOR target suppression (pS6) at equal doses for FYARROTM vs oral mTOR inhibitors resulting in higher anti-tumor activity in animal models. Its product, FYARROTM, is in phase II registrational trial for nab-sirolimus, ABI-009 in patients with advanced perivascular epithelioid cell tumors (PEComa).

Day's Change
0.415 (1.54%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 58,785 shares is on pace to be much greater than AADI's 10-day average volume of 51,927 shares.

  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    3:31p ET 10/28/21
  • Last (size)
  • 52-Wk Range
    14.31 - 49.80
  • (05/10/21 - 07/08/21)
  • 118.5%
  • Market Cap
  • Shares Outstanding
  • -6.07
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 1.4
  • 14.51
  • (% of float 10/15/21)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.